121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy
Nir Peled, Julien Mazières, Dariusz M. Kowalski, W-S. Lam, Maximilian J. Hochmair, Margarita Majem, Se Hoon Kim, Antonio Calles, Kristof Cuppens, Ignacio Casarini, Olivier Bylicki, Byoungyong Shim, Jens Benn Sørensen, Marina Gilli, Soon Hin How, Christian Schumann, Carmen González Arenas, Taiping He, Ayman Samkari, Silvia Novello
Topics & Concepts
DocetaxelPembrolizumabMedicineChemotherapyImmunotherapyOncologyInternal medicineCancerCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsLung Cancer Treatments and Mutations